Sepracor, Inc.

Sunovion Pharmaceuticals Inc.

Other

Wyeth

Swpracor, Inc.

Chrisantha Hugh Senanayake

Thomas P Jerussi

Qun Kevin Fang

Nandkumar N Bhongle

Roger P Bakale

Yaping Hong

Fran A McConville

Dhileepkumar Krishnamurthy

Zhengxu Han

Mark G Currie

John Richard Mccullough

Paul D Rubin

Tingjian Xiang

John R McCullough

Paul T Grover

Steven W Jones

Paul Grover

Zhi-Hiu Lu

Methods of preparing, and compositions comprising, derivatives of (&#x2212;)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

Methods of using derivatives of (&#x2212;)-venlafaxine

Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

Derivatives of venlafaxine and methods of preparing and using the same

Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HTantagonists.

Methods of treating or preventing erectile dysfunction

The invention encompasses methods of using racemic and enantiomerically pure norfluoxetine, as well as pharmaceutical compositions, pharmaceutical unit dosage forms, and kits comprising racemic and enantiomerically pure norfluoxetine. In particular, the invention encompasses a method of inhibiting or reducing the production of PGE. The invention further encompasses a method of treating or preventing inflammation in a patient, as well as a method of treating or preventing a disease or disorder such as, but not limited to, autoimmune diseases, arthritis, neurologic diseases, inflammatory diseases, fibromyalgia, pain resulting from inflammation, neuropathic pain, and cancer.

Methods of using norfluoxetine

Pharmaceutical compositions and dosage forms are disclosed that comprise a racemic or optically pure sibutramine metabolite and a phosphodiesterase inhibitor.

Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors

Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.

Methods of treating or preventing pain using sibutramine metabolites

The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (&#x2212;)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (&#x2212;)-N-desmethylzopiclone.

Methods of treating and preventing a convulsive state

Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (&#x2212;)-venlafaxine

Methods of treating or preventing neuropathic pain using sibutramine metabolites

Methods are disclosed for the treatment and prevention of obesity, weight gain, and eating disorders. The methods comprise the administration of racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof.

Methods of treating or preventing weight gain, obesity, and related disorders

The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (&plus;)-N-desmethylzopiclone, and optically pure (&minus;)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (&plus;)-N-desmethylzopiclone, and optically pure (&minus;)-N-desmethylzopiclone.

Methods of making and using N-desmethylzopiclone

Methods are disclosed for the treatment and prevention of male and female sexual function disorders which comprise a racemic or optically pure sibutramine metabolite and a phosphodiesterase inhibitor.

Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction

Methods of treating muscle spasms using N-desmethylzopiclone

Methods of preparing, and compositions comprising, derivatives of (&minus;)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

Growing community of inventors

Shrewsbury, MA, United States of America

Chrisantha Hugh Senanayake